

Electronic Recording and Reporting at Indus Hospital, Karachi, Pakistan



Aamir Khan, MD PhD
Executive Director
Indus Hospital TB Program
Interactive Research & Development






TB Program Overview

Updated till April 22, 2011

TB (all forms) case notification Indus Hospital DOTS Clinic 2007-2011



Indus Hospital DR-TB patients (Apr 13, 2011)

Treatment Status	XDR TB N(%)	MDR SUSPECT N(%)	MDR TB N(%)	PDR TB N(%)	MONO TB N(%)	MOTT N(%)	TOTAL N(%)
Registered	8	3	282	37	24	12	366
Enrolled	7 (88)	3 (100)	231 (82)	34 (92)	20 (83)	4 (34)	299 (81)

Round 9 SR for Sindh and Balochistan province 5500 MDR-TB patients to be put on treatment in Sindh/Balochistan

Rationale for ERR

- Private sector provider reporting to NTP must follow national R&R system
- Most patients treated in the private sector are not reported to NTP
- Need a system that can be implemented in both the private sector along with the public sector
- DR-TB patient management is complex











































Why ERR?

- Improved data quality
- Easier backup and storage
- Faster reporting
- Easier analysis
- Accessible remotely
- Role-based access allows security

Solution

- Open-source: low-cost of initial acquisition, moderate cost of operation
- Integration: 2 existing open-source solutions
 OpenMRS and openXdata
- Development: GIS visualization module for both OpenMRS and openXdata







- Open Medical Record System
 - in use since 2008
 - 600+ patients on the system
- MDR-TB module
 - Lab tests (smear, culture, DST)
 - Regimens
 - Tracking treatment e.g. conversion
 - Type of TB etc
 - Transitioning to version 2

OpenMRS Mobile

- MDR-TB DOT data via cell phone
 - Connects to OpenMRS
 - Treatment supporters visit patient daily
 - Enter DOT data on the cell phone
 - Real-time
 - Allows effective monitoring
 - Removes paper from the system
 - Improves data quality
 - Scale-up underway
 - Use can be expanded beyond DOT




TB horizon




Patient medical records



Patient medical records



Individual — Aggregate



OpenMRS MDR-TB module v2

- Currently in transition
- Faster system
- Better documented
- Easier to install and set up
- More user friendly
- Downside:
 - no data migration path from v1 to v2
 - development required to connect to openMRS mobile

Ba	cteriolog	ies		DSTs															
Smears	Cultures	Bacteria	INH	R	E	Z	s	СМ	КМ	АМК	CPX	OFX	LFX	Moxi	Ethio	CS	PAS	Prothio	TH
			_																
+++	POS	M. TUBERCULOSIS COMPLEX	R	R	R	R	R	S	S	S		R			S				
Treat	ment Star	t Date	Treatment Start Date																

Program Status

Enrollment Date: 24/Mar/2011 **Enrollment Location:** TB Clinic Indus

Registration Group - Previous Drug Use: PREVIOUSLY TREATED WITH SECOND LINE DRUGS

Registration Group - Previous Treatment: FAILURE OF CATEGORY I TREATMENT

Edit Program Close Program

Treatment Status: Currently on treatment

Regimen	Start Date	End Date	Туре
AMK + B6 + CS + Ethio + LFX + PAS + Z	24/Mar/2011	Present	

Edit Treatment

Visit Status

Intake: 18/Mar/2011 at TB Clinic Indus
Most Recent Follow-up: 24/Mar/2011 at TB Clinic Indus

Next Scheduled Follow-up: None

Add Follow-up Visit

Hospitalizations: Not currently hospitalized

Add Hospitalization

MDR-TB Diagnosis

Resistance Type: Confirmed MDR-TB **Resistance Profile:** INH + R + E + Z + S + OFX

Site: Pulmonary

	Result	Date Collected	Lab	Date completed
Diagnostic Smear	STRONGLY POSITIVE (+++)	24/Sep/2010	AKU Hospital	25/Sep/2010
Diagnostic Culture	POSITIVE	24/Sep/2010	AKU Hospital	03/Nov/2010

Bacteriology Status

Smear Status: Not Converted Culture Status: Not Converted

	Result	Date Collected	Lab	Date completed
Most Recent Smear	STRONGLY POSITIVE (+++)	24/Sep/2010	AKU Hospital	25/Sep/2010
Most Recent Culture	POSITIVE	24/Sep/2010	AKU Hospital	03/Nov/2010

Add Test Results

HIV Status: Unknown

Most Recent Test Result: Unknown

ART Treatment: Currently not on treatment

Current Regimen: None
Most Recent CD4 Count: Unknown



Home | MDR TB

Another calculation

Count Patients Taking TUBERCULOSIS TREATMENT DRUGS for All patients in system (221 patients) on 27/04/2011

	Medication	# patients
Amoxicillin/Clavulantic Acid (Amx	/Clv) AMOXICILLIN AND CLAVULANIC ACID mg	4
Clarithromycin (Clr)	CLARITHROMYCIN mg	2
Cycloserine (Cs)	CYCLOSERINE mg	14
Ethambutol (E)	ETHAMBUTOL mg	12
Ethionamide (Eto)	ETHIONAMIDE mg	15
Kanamycin (Km)	KANAMYCIN mg	18
Moxifloxacin (Mfx)	MOXIFLOXACIN mg	6
Ofloxacin (Ofx)	OFLOXACIN mg	13
P-aminosalyicylic acid (PAS)	P-AMINOSALICYLIC ACID mg	7
Pyrazinamide (Z)	PYRAZINAMIDE mg	2
RHEZ	RIFAMPICIN ISONIAZID PYRAZINAMIDE AND ETHAMBUTOL 1.0 tab(s)	1
Rifampicin (R)	RIFAMPICIN mg	3




Currently logged in as Super User | Log out | My Profile | MDR TB Help

Home | MDR TB

Another calculation

Drug Usage Calculation for TUBERCULOSIS TREATMENT DRUGS for All patients in system (221 patients) from 01/01/2008 to 31/12/2008 (365 days)

Me	edication	Average Daily Usage	Total Quantity Required	Price per unit	Cost for this drug
Amikacin (Am)	AMIKACIN mg	67.1	24500.0	x \$ 0.5 =	\$12250
Cycloserine (Cs)	CYCLOSERINE mg	75.3	27500.0	x \$ 0.75 =	\$20625
Ethambutol (E)	ETHAMBUTOL mg	667.3	243600.0	x \$ =	\$0
Ethionamide (Eto)	ETHIONAMIDE mg	323.9	118250.0	x \$ =	\$0
Kanamycin (Km)	KANAMYCIN mg	367.8	134250.0	x \$ =	\$0
Ofloxacin (Ofx)	OFLOXACIN mg	1126.5	411200.0	x \$ =	\$0
P-aminosalyicylic acid ((PAS) P-AMINOSALICYLIC ACID mg	7320.5	2672000.0	x \$ 0.33 =	\$881760
Rifampicin (R)	RIFAMPICIN mg	461.5	168450.0	x \$ =	\$0
				Total cos	t: \$914635



Challenges

- Requires dedicated IT staff
- High memory consumption in older software version
 - New version and dedicated hardware have helped
- Initial implementation requires a lot of effort
 - From IT staff
 - From program staff
 - From clinical staff
- Interaction with Indus Hospital's HMIS
 - In the works

Mobile phone based Conditional Cash Transfer

Indus TB REACH grant


- GPs: identifying and referring suspects, TB case confirmation, cure/completion
- CHWs: household contact tracing, identifying and referring suspects, TB case confirmation, cure/completion

Q1 2011 in comparison to Q4 2010 Indus Hospital DOTS Clinic 2010-2011


- 108% increase in all forms TB
- 125% increase in pulmonary TB
- 133% increase in SS+ pulmonary TB
- 114% increase in SS- pulmonary TB
- 75% increase in extra-pulmonary TB
- 44% increase in childhood TB

Indus Hospital has become the **highest DOTS** reporting center in Sindh province in Q1 2011


Percent change over previous quarter in DOTS TB (all forms) case notification Indus Hospital DOTS Clinic 2010-2011



Projections: DOTS TB registration at April 2011 rate Indus Hospital DOTS Clinic 2010-2011



Pediatric TB cases at Indus Hospital: Annual enrollment and Reporting to NTP



2010: Children accounted for 20% (142/709) of total TB cases

HIV, HCV & HBV Serology Status in Registered DR TB Patients (Apr 13, 2011)

Results	HIV N(%)	HCV N(%)	HBV N(%)	
Reactive	2 (1)	35 (13)	11 (4)	
Borderline	0	4 (2)	0	
Non-reactive	324 (99)	222 (85)	248 (96)	
Total Tested	326	261	259	

HbA1c > 6.5% in Registered DR TB Patients (Apr 13, 2011)

Age Range N(%)	Propo		tive of Total	Total Patients >6.5%	Total Tested N	
	V	lale				
	>6.5	Tested	>6.5	Tested		
0-<15	0	5	0	6	0	11
15-<25	3 (10)	31	6 (11)	55	9 (10)	86
25-<35	5 (21)	24	2 (7)	28	7 (13)	52
35-<45	10 (32)	31	4 (20)	20	14 (27)	51
45-<55	3 (27)	11	4 (36)	11	7 (32)	22
55-<65	2 (25)	8	2 (33)	6	4 (29)	14
>65	1 (50)	2	0	2	1 (25)	4
Total	24 (21)	112	18 (14)	128	42 (18)	240

Key lessons learnt & advice for countries

- The R&R system must provide useful feedback to data generators
- TB is a complex disease; ERR systems need to allow for locally relevant data points
- Partnerships are key. There is no single solution available for countries.
- Visit ERR sites before selecting a system.









Massachusetts Institute of Technology











